Cellectis Inc. (CLLS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please stand by, your program is about to begin. If you need assistance during the conference today, please press star zero. Good day, everyone, and welcome to today's Selectus second quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star one on your telephone keypad. you may withdraw yourself from the queue by pressing star two. Please note this call may be recorded and I'll be standing by should you need any assistance. It is now my pleasure to turn the conference over to Arthur Strill, Interim Chief Financial Officer. Please go ahead. Good morning and welcome everyone to Selectus' second quarter 2025 business update and financial results conference call. Joining me on the call today are Dr. André Choulika, our Chief Executive Officer, and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Selectus issued a 6K in press release reporting our financial statements for the six-month period ended June 30, 2025, and a business update. The report and press release are available on our website at selectus.com. As a reminder, We will make statements regarding Selectis' financial outlook, including the presentation of our Bally 01 and Natalie 01 clinical trials, the timing and ability to progress our clinical trial into a later phase, the progress of our R&D activities under the AstraZeneca partnership, the timing and outcome of our arbitration with Servier, and sufficiency of cash to fund operations. These forward statements, which are based on our management's current expectations and assumptions, and on information currently available to management, including ...